News & Updates
COVID-19 News & Updates
Curated articles on the latest COVID-19 strains, treatments, side effects, testing guidance, Long COVID research, and prevention — all sourced from the CDC, WHO, NIH, and FDA.
Variants & Surveillance
Latest Strains & Variants
Current SARS-CoV-2 variants under WHO and CDC monitoring, including NB.1.8.1, XFG, BA.3.2, and PQ.16.1.1.
NB.1.8.1 Leads Global Sequences; XFG Declining
In the period ending 21 June 2026, NB.1.8.1 accounted for about 50% of globally submitted sequences (up from 35%), while XFG fell to about 17%. JN.1 accounted for about 21% and BA.3.2 about 9%. WHO reports no elevated severity signal for these lineages.
WHO Designates PQ.16.1.1 as Variant Under Monitoring
On 27 July 2026 WHO designated PQ.16.1.1 (a descendant of NB.1.8.1) as a Variant Under Monitoring. Most sequences have been reported from the Western Pacific Region, especially Singapore. Initial risk evaluation: low, with growth advantage noted where sequencing continues.
Current VUMs: NB.1.8.1, XFG, BA.3.2, PQ.16.1.1
As of 27 July 2026, WHO lists Variants Under Monitoring: PQ.16.1.1, NB.1.8.1, XFG, and BA.3.2. JN.1 remains a Variant of Interest. BA.3.2 is more divergent but has not displaced JN.1-descendant lineages globally; dynamics vary by region.
U.S. Surveillance: NB.1.8.1 (Nimbus) Prominent in Mid-2026
U.S. genomic and wastewater data through mid-July 2026 showed NB.1.8.1 (sometimes called Nimbus) becoming a leading lineage in many states, with emergency department COVID visits rising in some periods. CDC continues genomic and respiratory virus tracking.
2026–2027 Vaccine Formula: Monovalent XFG Recommended
FDA VRBPAC recommended that the 2026–2027 U.S. COVID-19 vaccine formula be a monovalent JN.1-lineage XFG vaccine for use beginning fall 2026. Manufacturers indicated readiness to supply. Current 2025–2026 formulations remain available until the new season.
Antivirals & Therapeutics
Treatments & Antivirals
Authorized COVID-19 treatments including Paxlovid, Remdesivir, and Pemgarda — how they work and who should use them.
Paxlovid (Nirmatrelvir/Ritonavir): What You Need to Know in 2026
Paxlovid remains the most widely available oral antiviral for COVID-19. It must be started within 5 days of symptom onset and is authorized for adults and children 12+ at high risk. Drug interactions are common — check with your pharmacist before starting.
Remdesivir (Veklury) Remains FDA-Approved for Hospitalized and Outpatient Use
Remdesivir is FDA-approved for adults and children with COVID-19, administered as a 3-day IV infusion within 7 days of symptom onset. It remains a preferred treatment in hospital settings and is available at many infusion centers for outpatients.
Pemgarda (Pemivibart): Preventive Option for Immunocompromised Patients
Pemgarda, a monoclonal antibody, has been authorized as COVID-19 pre-exposure prophylaxis for moderately to severely immunocompromised individuals aged 12+ who weigh at least 88 lbs. CDC and FDA continue to monitor variant impact on effectiveness.
NIH COVID-19 Treatment Guidelines: Updated Recommendations for Clinicians
The NIH COVID-19 Treatment Guidelines Panel continues to update evidence-based clinical guidance for healthcare providers. Guidance covers outpatient antivirals, remdesivir dosing, immunocompromised patient protocols, and Long COVID management.
Don't Delay: Why Timing Is Critical for COVID-19 Antiviral Treatment
COVID-19 antiviral medications must be started within 5–7 days of symptom onset to be effective. CDC warns that waiting too long significantly reduces their benefit. High-risk individuals should contact a provider promptly if symptoms develop.
Safety & Adverse Events
Side Effects & Safety
Vaccine safety data, antiviral side effects, Paxlovid rebound, drug interactions, and Long COVID organ effects.
Paxlovid Rebound: What the Evidence Shows
COVID-19 rebound — a return of symptoms or a positive test 3–7 days after recovering — can occur with or without antiviral treatment. Studies confirm that rebound after Paxlovid does not increase the risk of severe illness, and the benefits of treatment still outweigh the risk.
COVID-19 Vaccine Safety Monitoring: Ongoing Season Summary
CDC's Vaccine Safety Datalink and VAERS systems continue to monitor COVID-19 vaccine formulations. The most common side effects remain injection site pain, fatigue, and headache. Myocarditis risk in young males remains extremely low and far below COVID-19 infection risk.
Common Drug Interactions with Paxlovid: A Guide for Patients
Paxlovid's ritonavir component is a potent inhibitor of CYP3A enzymes and interacts with many medications including statins, blood thinners, antidepressants, and immunosuppressants. Patients should always run an interaction check before starting treatment.
Long COVID's Neurological Side Effects: Brain Fog, Fatigue, and Memory Issues
Emerging research from NIH's RECOVER Initiative confirms that neurological symptoms — including cognitive impairment ("brain fog"), persistent fatigue, and memory difficulties — are among the most prevalent and debilitating Long COVID effects.
Post-COVID Cardiac Effects: What Patients and Providers Should Know
Studies continue to document an increased risk of cardiac complications — including myocarditis, pericarditis, arrhythmias, and elevated cardiovascular event risk — in the months following acute COVID-19 infection, particularly in unvaccinated individuals.
Testing & Diagnosis
Diagnosing & Testing
PCR vs. antigen tests, how to interpret results, when to retest, and where to find free testing in your area.
PCR vs. Rapid Antigen Tests: Which Should You Use?
PCR (NAAT) tests are the gold standard and most sensitive option, but require lab processing. Rapid antigen tests provide results in 15–30 minutes at home but are less sensitive, particularly without symptoms. FDA recommends 2–3 antigen tests 48 hours apart for a reliable negative result.
FDA's List of Authorized At-Home COVID-19 Tests
The FDA maintains a continually updated list of authorized at-home COVID-19 antigen tests. Not all tests on the market are FDA-authorized — consumers should verify their test is on this official list before purchase.
Testing After Recent COVID-19 Infection: A Practical Guide
If you tested positive within the last 90 days, standard testing recommendations change. PCR tests can stay positive for up to 90 days after infection. CDC recommends antigen tests for new symptoms and cautions that reinfections within this window can occur but are harder to detect.
How to Interpret a Negative Rapid Test When You Have Symptoms
A single negative rapid antigen test does not rule out infection. If you are symptomatic, the CDC and FDA recommend retesting at 48-hour intervals for a total of two negative results — or using a PCR test for confirmation.
Find Free or Low-Cost COVID-19 Testing Near You
Free COVID-19 NAAT and antigen testing may be available through your local health department, community health centers, and pharmacies. Uninsured and underinsured patients can often access no-cost testing at federally qualified health centers.
Post-COVID Conditions
Long COVID & Recovery
Latest research on Long COVID symptoms, NIH RECOVER findings, treatment approaches, and mental health support.
NIH RECOVER Initiative: Latest Findings on Long COVID Symptoms
The NIH RECOVER Initiative — the largest federally funded Long COVID research program — has identified core symptoms most predictive of Long COVID, including post-exertional malaise, fatigue, brain fog, and palpitations. Enrollment in clinical trials remains open.
CDC's Long COVID Overview: Symptoms, Causes, and Who Is at Risk
CDC defines Long COVID (Post-COVID Conditions) as a wide range of new, returning, or ongoing health problems occurring four or more weeks after infection. Symptoms can last months or years. Vaccination reduces but does not eliminate the risk.
Paxlovid May Reduce Long COVID Risk, Studies Suggest
Multiple observational studies suggest that early antiviral treatment with Paxlovid may reduce the likelihood of developing Long COVID, particularly in high-risk populations. Ongoing clinical trials through NIH RECOVER are studying this association further.
Managing Long COVID: A Guide to Pacing, Rehabilitation, and Care
Medical experts recommend a paced rehabilitation approach for Long COVID patients, especially those with post-exertional malaise (PEM). Aggressive exercise can worsen symptoms. Specialist Long COVID clinics offer multidisciplinary care.
Mental Health and Long COVID: Addressing Depression, Anxiety, and PTSD
Studies find elevated rates of depression, anxiety, and PTSD among Long COVID patients. SAMHSA's National Helpline (1-800-662-4357) and COVID-specific support groups provide free, confidential mental health assistance.
Vaccines & Prevention
Prevention & Vaccines
2026–2027 XFG vaccine formula, WHO SAGE risk-based recommendations, CDC prevention strategies, and high-risk guidance.
2026–2027 COVID-19 Vaccine: XFG Formula Recommended for Fall
FDA advised manufacturers that the 2026–2027 U.S. COVID-19 vaccine formula should be monovalent XFG (JN.1 lineage) for use beginning fall 2026. Until then, 2025–2026 vaccines remain available. Priority remains highest for adults 65+, immunocompromised people, and other high-risk groups.
WHO SAGE: Routine Vaccination for Highest-Risk Groups
WHO SAGE recommends that countries consider routine COVID-19 vaccination for groups at highest risk of severe disease, including older adults and moderately or severely immunocompromised people aged ≥6 months, with at least one dose per year when previously vaccinated more than 6 months earlier.
Core Prevention Strategies: CDC Respiratory Virus Guidance
CDC Respiratory Virus Guidance recommends staying up to date on vaccines, practicing good hand hygiene, improving indoor air quality, and isolating when sick. Additional strategies include masking in crowded spaces and testing before visiting high-risk individuals.
Respiratory Virus Activity Levels in Your Community
CDC updates respiratory virus activity data weekly at the county, state, and national levels. Checking your community's current activity level can help you decide when to take additional precautions, particularly if you live with or care for high-risk individuals.
COVID-19 and Pregnancy: Latest Guidance for Expecting Parents
Pregnant people remain at higher risk for severe COVID-19. CDC recommends vaccination during pregnancy and up-to-date boosters. Paxlovid, Remdesivir, and other treatments have specific pregnancy guidance — consult your OB-GYN before taking any COVID-19 antiviral.
Misinformation & Debunking
Latest Conspiracy's
High-visibility COVID conspiracy related coverage and research references, prioritized from top-ranking search results.
A Systematic Review of COVID-19 Conspiracy Beliefs Worldwide
Peer-reviewed global review of COVID-19 conspiracy belief prevalence across countries and regions, including common narratives and public-health implications.
COVID-19 Misinformation: Major Conspiracy Narratives and Their Spread
Comprehensive overview of how core COVID-19 conspiracy narratives spread online, including origin myths, prevention myths, and behavior-level impacts.
Why COVID Origin Conspiracies Persist and Why It Matters
Coverage of the continuing COVID-origin conspiracy cycle and the downstream effect on scientific trust and future pandemic preparedness.
Why Do People Believe COVID-19 Conspiracy Theories?
Harvard Kennedy School Misinformation Review article examining psychological and social drivers behind belief in major COVID-19 conspiracy claims.
Conspiracy Beliefs and Public Health Behavior During COVID-19
Open-access research on how COVID conspiracy beliefs correlate with lower compliance for prevention guidance and increased misinformation acceptance.